secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2021-09-03T23:59:59+00:00
Accession:  0001193125-21-265510
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences Q2 revenue $30.4M (+59% YoY); operating income turns positive at $3.8M
--------------------------------------------------------------------------------

- Revenue $30.4M, +59% YoY; gross margin improved to 65% from 43%.
- Operating income $3.8M vs. ($0.2M) a year ago; net income $2.7M down from $8.1M.
- Installed base reached 855 instruments, with 104 placements in Q2.
- Launched Aurora Cell Sorter and Automated Sample Loader during the quarter.
- Completed IPO in July 2021, raising $215M in net proceeds to strengthen balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312521265510/0001193125-21-265510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312521265510/d187138d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-265510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer